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Abstract: Adjustment disorders (AjD) with depressive symptoms following an acquired brain injury
(ABI) is a common phenomenon. Although brain injuries are increasing more and more, research on
psychological therapies is comparably scarce. The present study compared, by means of a randomized
controlled trial (RCT), a newly developed integrative treatment (Standard PLUS) to a standard
neuropsychological treatment (Standard). Primary outcomes were depressive symptoms assessed
with the Beck Depression Inventory (BDI-II) at post-treatment and 6-month follow-up assessment.
In total, 25 patients (80% after a stroke) were randomized to one of the two conditions. Intention-to-treat
analyses showed that the two groups did not significantly differ either at post-treatment nor at
follow-up assessment regarding depressive symptoms. Both treatments showed large within-group
effect sizes on depressive symptoms. Regarding secondary outcomes, patients in the Standard PLUS
condition reported more emotion regulation skills at post-assessment than in the control condition.
However, this difference was not present anymore at follow-up assessment. Both treatments showed
medium to large within-group effects sizes on most measures for patients suffering from an AjD after
ABI. More research with larger samples is needed to investigate who profits from which intervention.
Keywords: acquired brain injury; cognitive rehabilitation; neuropsychology; psychotherapy;
adjustment disorders; stroke
1. Introduction
A stroke is one of the most common causes of disability acquired in adulthood and is a common
cause of death and adult disability worldwide [1]. In the last 20 years, the incidence rate of ischemic
and hemorrhagic stroke increased significantly [2]. Improvements in medical treatment for stroke has
advanced rapidly, and more people survive but live with the consequences of stroke [3].
Patients with stroke have to cope with direct consequences of the brain injury (e.g., memory or
attention impairments, language problems, hemiparesis, and visual problems) as well as secondary
consequences (e.g., loss of experiences at work and in social functioning). These fundamental and
lifelong changes trigger a sense of substantial uncertainty in most patients, as essential areas of their
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lives are threatened [4,5]. As a consequence, it is not surprising that around 50% of acute stroke
survivors have residual major physical or cognitive deficits and need assistance for adaptation and
coping with the complex physical and social sequelae of stroke [6].
People with acquired brain injury (ABI) are at increased risk of developing emotional disturbances
compared to the general population [7]. Many stroke patients adjust well to their changed life conditions,
whereas others develop serious symptoms of mood disorders such as feelings of worthlessness and
sense of loss, and complete restoration is not always possible [4]. Studies estimate that about one-third
of patients suffer from mood disorders after stroke [8–10]. It is generally assumed that emotional
disturbance following ABI might be a direct result of structural brain lesions (e.g., the location of
the lesion) [11,12]. Alternatively, it is suggested that physical limitation (e.g., hemiparesis), cognitive
impairments (e.g., loss of memory or language), and social and psychological stressors (e.g., the ability
to cope with the illness) are associated with mental disorders [13–15]. Thus, it seems reasonable
to assume that emotional disorders following stroke appear to be a biopsychosocial multifactorial
illness [16–19].
Various studies have shown that untreated adjustment disorders (AjD) can severely restrict the
potential for rehabilitation of stroke patients and can hinder their re-entry into work. Moreover,
a Danish study showed that around 50% of these patients had left their jobs permanently or were still
on sick leave one year after stroke [20]. Another study revealed that six years after stroke, 84% have
returned to work but only 35% reached the same level of work ability [21]. In the long term, they also
represent the greatest strain on the family [22]. Nevertheless, so far, surprisingly little attention has
been given to AjD in terms of research, despite the increased number of AjD in primary care [23,24].
One reason might be that neither the international classifications system DSM-IV nor the international
classification of diseases and related health problems ICD-10 includes specific diagnostic criteria for
mental disorders such as AjD due to brain injury. Hence, it is treated differently in various studies.
Moreover, some researchers define “mental disorder after stroke” as major or minor depression [25,26],
while others classified it as an AjD brought on by a stressful life change [27]. According to the DSM-IV,
AjD is characterized by persistent maladaptive emotional or behavioral response to an identifiable
psychosocial stressor, to which patients experience difficulties adjusting after a stressful event [28].
Numerous studies have shown that untreated mood disorders or AjD have a predictive negative
impact on daily activities [29], cognition [30], and rehabilitation [31,32], as well as increased mortality
rate [33]. Moreover, untreated psychological problems can further exacerbate social difficulties after
ABI, often leading to significantly reduced quality of life, substantially reduced psychological coping
capacities, and additional deterioration [34].
To date, many theoretical considerations about ways of dealing with mood disorders after ABI
exist in order to improve rehabilitation outcome [35–37]. In general, management of mood disorders
or AjD after stroke includes antidepressants and psychotherapy [10]. Regarding antidepressants,
a Cochrane review [38] including 56 randomized controlled trials provided strong support for the
efficacy of antidepressants (e.g., selective serotonin reuptake inhibitors; SSRIs) following stroke in
patients with mood disorders. Despite the positive effects of antidepressant treatment, there is no
conclusive evidence regarding the optimal length of antidepressant treatment for mood disorders [39].
Moreover, antidepressant treatments also may have many side effects and risks, including an increased
risk of hemorrhagic complications and falls [40].
Regarding psychotherapy, a systematic review found preliminary evidence supporting the efficacy
of cognitive behavior therapy (CBT) for depression following ABI [41]. Another meta-analysis revealed
an overall effect size of 0.69, suggesting a medium effectiveness of psychological interventions on mood
disorders compared to control conditions [42]. Therefore, CBT interventions for psychological distress
in people with ABI might have the potential to improve psychological well-being, but there is still a lack
of evidence-based treatment studies for mental disorders following stroke [5]. A recent Cochrane review
by Gertler and colleagues [43] identified three eligible studies evaluating CBT or mindfulness-based
therapy compared to a control intervention (waitlist group or supportive therapy) for ABI patients
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suffering from mood disorders. In terms of reduction of depressive symptoms, they did not find an
effect in favor of treatment, but there was very low-quality evidence (e.g., high attrition bias), small effect
sizes, and wide variability of results. Moreover, Ashman and colleagues [44] evaluated in a randomized
controlled trial comparing CBT and supportive psychotherapy for the treatment of depression following
traumatic brain injury. The main results revealed that there was no significant difference between
groups regarding the level of depressive symptoms at post-assessment. Furthermore, a recent
published pilot randomized controlled trial showed that acceptance and commitment therapy (ACT)
may facilitate adjustment after traumatic brain injury and revealed significant changes regarding stress
and depressive symptoms after post-assessment compared to an active control condition. However,
this reduction of stress and depressive symptoms was not maintained at follow-up assessment nor did
the primary outcome (psychological flexibility) differ significantly at any assessment point between
the two groups [45]. In a non-controlled pilot study, Hofer and colleagues [46] tested an integrated
treatment program in which neuropsychological interventions are supplemented by psychotherapeutic
interventions to foster the adjustment process. Results indicated a large within-group effect size of
1.30 on the Beck Depression Inventory (BDI-II). In addition, patients showed significant within-group
changes regarding three coping styles (decrease of rumination, increase of searching for social support,
and cognitive coping).
The combination of neuropsychological and cognitive–behavioral approaches for treating
psychological sequelae following ABI has drawn more attention during recent years. Unfortunately,
a paucity of randomized controlled trials limits drawing convincing conclusions [47]. A recent
systematic review showed that CBT and family and systemic therapies are recommended at all stages
in the evolution of appropriate therapeutic interventions of mood disorders following ABI [48].
The main aim of the present study was to investigate by means of a randomized controlled trial
whether an integration of neuropsychological and psychotherapeutic treatment is more effective than
a neuropsychological treatment alone in ABI patients diagnosed with an AjD, which is one of the
most under-researched psychiatric disorders [49]. Furthermore, we hypothesized that the intervention
group (Standard PLUS) will show a greater reduction in depressive symptoms (BDI-II) compared to
the control condition (Standard group, i.e., neuropsychological treatment alone).
2. Materials and Methods
This randomized controlled trial (RCT) compared an intervention group with an active control
group. The trial was registered with http://www.clinicaltrials.gov/ (NCT01039857) and was approved
by the Ethics Committee of the Canton of Bern, Switzerland (012/08) on 23/10/09.
2.1. Patients
Patients were recruited via the outpatient setting of the University Neurorehabilitation of
the Department of Neurology, University Hospital, Inselspital, Bern. Inclusion criteria were
(a) being between 18 and 66 years, (b) time passed since stroke having been more than six months
(e.g., with regard to spontaneous remission [50]), (c) having a diagnosis of an adjustment disorder
(DSM-IV: 309.x, acute or chronic), and (d) having the sufficient ability to communicate in German.
Criteria for exclusion were (a) the presence of another chronic disease (e.g., multiple sclerosis, sarcoidosis,
Parkinson disorder, neurodegenerative illness, chronic pain disorder, rheumatic disorder), (b) a prior
history of a neurological disease, (c) a prior history of a mental disorder, and (d) acute suicidality or
violent behavior.
After returning the signed informed consent form, participants completed an initial
neuropsychological assessment and were interviewed by the therapist using the Structured Clinical
Interview for DSM-IV Axis I Disorder (SCID-I) [51] to check the diagnostic criteria for an adjustment
disorder. All interviews were supervised by the senior author. After the interview, participants were
asked to complete the baseline questionnaires. In addition, a comprehensive neuropsychological
examination, including measures of memory, attention, and executive and visual functioning was
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performed for each patient before the beginning of the neuro-psychotherapy to ensure insufficient
cognitive abilities. Patients with severe cognitive impairments or sufficient language abilities were
excluded from the study.
At the beginning of recruitment, we mainly focused on stroke patients. Due to problems with
recruitment of patients, (e.g., challenging medical condition in the context of the given health care
system and homogeneity of the study sample), we widened the inclusion criteria during the trial, and
any kind of non-progredient ABI (n = 5; e.g., traumatic brain injury or encephalitis) was included.
A total of 25 participants who fulfilled inclusion criteria were randomly assigned to one of the two
conditions. Randomization took place at the Insitute of Social and Preventive Medicine University
Bern, which gave feedback to the researcher regarding group allocation according to a pre-generated
randomization sequence. Participants were randomized in a 1:1 ratio. The flowchart of the present
study is depicted in Figure 1.
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2.2. Measures
The following measures were applied at several time points (baseline, post-treatment and 6-month
follow-up). The questionnai s were handed over to th atients perso ally and administered on paper.
In addition, Goal Attainment Scaling (GAS-R) was performed at pre- and post-tre t e t (see below).
2.3. Primary Outcome
The primary endpoint of the present study was the Beck Depression Inventory II (BDI-II; [52])
at post-treatment and 6-month follow-up after post-treatment. The BDI-II is a self-report measure
consisting of 21 items describing symptoms of depression. The total score ranges from 0 to 63, with a
higher score indicating more depressive symptoms. The BDI-II has been widely used in different
populations, including patients with a brain injury [53]. The internal consistency in the present sample
was α = 0.90.
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2.4. Secondary Outcomes
Quality of Life. To assess the quality of life, a short form of the World Health Organization Quality
of Life (WHOQOL-BREF) was administered [54]. The WHOQoL-BREF uses 26 items to measure
self-assessed quality of life with regard to mental well-being, physical well-being, social relationships,
and the environment. In the present study, we report a sum score over all items. Cronbach’s α in the
present study was 0.87.
2.4.1. Acceptance of Disability
To assess the level of acceptance of disability, a revised version of the Acceptance of Disability
Scale (ADS) was applied [55,56]. The ADS has 32 items and uses a four-point Likert scale which
measures an individual’s overall acceptance of a disability (e.g., “With my disability all areas of my life
are affected in some major way”). Cronbach’s α in the present study was 0.81.
2.4.2. Awareness
In order to assess the level of awareness, we used the Awareness Questionnaire (AQ) [57]. The AQ
was developed as a measure of impaired self-awareness after traumatic brain injury (TBI). The AQ
includes three forms; one form is completed by the person with TBI (AQ_P), one by a significant other
of the patient (AQ_R), and one by the therapist (AQ_T). The self-rated and family/significant others
forms include 17 items (e.g., “How well can you concentrate now as compared to before your injury?”),
while the therapist form has 18 items (e.g., “How well can the patient concentrate now as compared to
before his/her injury”). On each form, the abilities of the person with TBI to perform various tasks after
the injury as compared to those before the injury and rated on a 5-point Likert scale ranging from 1
(“much worse”) to 5 (“much better”) [58]. Cronbach’s α in the present study for the self-rated form
was 0.81, for the family/significant others form, 0.83, and for the therapist form, 0.61.
2.4.3. Illness Coping
Different coping behaviors of the patients were assessed with the Trier Illness Coping Scales
(TSK) [59]. The standardized questionnaire includes 37 items with a 6-point Likert scale, which are
combined into five subscales, and characteristics of cognitive and behavioral strategies of coping are
assessed. The five subscales are the following. Rumination specifies brooding thoughts about previous
illness-related problems. Patients with high scores on this scale are searching for causes of their illness
in the past and draw comparisons to the time before disease onset (e.g., “I was worried whether the
doctor may help me”). Defense of threat is an intrapsychic coping style that combines palliative cognitive
reactions like revaluation and downward comparison (e.g., “I had a good time with other people”).
Search for social integration describes turning toward the social environment to mobilize emotional
support and to distract from illness-related problems (e.g., “I enjoyed myself outdoors in nature”).
Search for information characterizes an active coping style, where patients are looking for social support
and information about the disease and treatment options in an active manner (e.g., “I exchanged
experiences in dealing with the disease with other patients”). Search for support in religion is a scale
which reflects the personal preferences for religion as a coping resource (e.g., “I prayed and sought
consolation in the faith”). Cronbach’s α in the present study was for Rumination 0.73, Defense of threat
0.83, Search for social integration 0.78, Search for Information 0.76, and Search for support in religion 0.77.
2.4.4. Emotion Regulation Skills
General emotion-regulation skills were assessed with the Emotion Regulations Skills Questionnaire
(ERSQ) [60]. The ERSQ is a 27-item self-report measure that assesses the application of
emotion-regulation skills during the previous week on a 5-point Likert scale (1 “not at all” to 5
“almost always”). It contains nine scales that correspond to the nine emotion regulation skills. Items
are preceded by the stem “Last week . . . .” and include e.g., “ . . . I paid attention to my feelings” or “
J. Clin. Med. 2020, 9, 1684 6 of 17
. . . my physical sensations were a good indication of how I was feeling”. Cronbach’s α in the present
study for the total score was 0.95.
2.4.5. Relationship Quality
To assess the statisfaction in the relationship, the Relationship Assessment Scale (RAS) was
used [61]. The RAS includes seven items that are rated on a 5-point Likert scale with scores ranging
from 1 to 5 (e.g., “Overall, how satisfied are you with your relationship?”). Higher scores reflect
higher relationship satisfaction. This questionnaire was only completed by participants with a partner.
Cronbach’s α in the present sample was 0.99.
2.4.6. Mental Fatigue
Mental fatigue was assessed by means of an abbreviated 6-item version of the Mental Fatigue
Scale (MFS) [62]. Answers were given on a 4-point Likert scale from 0 to 3. Cronbach’s α in the present
sample was 0.79.
In addition to the measures above, at the beginning of the therapy, each patient defined her
or his individual therapy goals using a modified version of the Goal Attainment Scaling procedure
(GAS-R) [63]. Goal attainment scaling involved the following steps: (a) participants were asked to
specify the most important therapy goals at baseline; (b) on a continuum of possible outcomes between
−2 (worst expected outcome) and +4 (best expected outcome), pretreatment performance was set at
0; (c) criteria for scoring at each level were specified; and (d) participants were asked to evaluate the
extent of goal attainment at post-treatment. The therapists were instructed to define at least two goals
together with the patients. The average score of all three goals at post-assessment was used as an
outcome measure.
3. Treatments
As noted above, in the present study, two treatment conditions were compared: the standard
treatment (Standard) and the standard plus treatment (Standard PLUS). Both treatment programs
were manualized (for a detailed summary, see Table 1). All therapies were carried out by three female
psychologists qualified as psychotherapists and neuropsychologists. For every patient, an individual
treatment plan was formulated. The duration of the treatment program was not limited a priori,
but instead adapted to suit each patient’s individual needs. However, the general aim was to achieve
the therapy goals within 20 sessions over the course of one year.
The Standard treatment contained solely the treatment of neuropsychological disorders caused
by an ABI as well as their effects on everyday life. The program was based on conventional
recommendations for neuropsychological outpatient rehabilitation [64–66]. The psychological
interventions followed a mainly psychoeducational rationale focusing on problem-solving and coping.
No specific psychotherapeutic interventions as mentioned in the “Standard PLUS” program below,
such as focusing on emotional processes, were included.
In the Standard PLUS treatment, neuropsychological interventions were combined with
evidence-based psychotherapeutic interventions [46,67]. The psychotherapeutic interventions were
adapted from cognitive–behavioral, emotion-focused, process-experiential as well as interpersonal
psychotherapies [68–70]. The additional psychotherapeutic components included focus on the
emotional aspects of coping during the emotional adjustment to the consequences of an ABI, conscious
redefinition of one’s role in one’s social and occupational life, and re-evaluating one’s hopes, fears,
and expectations for the future.
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Table 1. Overview of the treatments.
Phase Standard Treatment Standard PLUS Treatment
Preparatory
(Week 1)
Establishing a sustainable working alliance,
information about the aims and procedures of the
therapy. Formulation of individual therapy goals and
introduction of a tiredness diary.
Analogs to the standard treatment procedure week 1
Intervention
(Week 1–18)
Implementation of the standard therapy, with the
aim of achieving individual therapy goals by the 18th
session.
Implementation of the standard PLUS Therapy,
with the aim of achieving individual therapy goals by
the 18th session.
Important topics:
- Improvement of functional level
- Achievement of the best possible degree of
independence in everyday life
- Provision of information: education and
information about the brain injury and its
consequences a
- Dealing with a changed degree of tiredness
Important topics:
- Improvement of functional level
- Achievement of the best possible degree of
independence in everyday life
- Provision of information: education and
information about the brain injury and its
consequences a
- Dealing with a changed degree of tiredness
- Training of emotional competence
- Adjustment to the changed possibilities
Therapeutic interventions:
- Restitution b of cognitive functions.
- Compensation b for any functional deficits
(e.g., the use for external memory aids)
- Coping b with the consequence of injury (e.g.,
memory problems, dealing with tiredness)
- Integrated techniques as operant conditioning
techniques (e.g., cognitive self-teaching
techniques, self-management) c
Therapeutic interventions:
- Restitution b of cognitive functions.
- Compensation b for any functional deficits
(e.g., the use for external memory aids)
- Coping b with the primary (e.g., memory
problems, dealing with tiredness) and
secondary consequence of injury
- Integrated techniques as operant conditioning
techniques (e.g., cognitive self-teaching
techniques, self-management) c
PLUS: Psychotherapeutic techniques (e.g., emotional-focus
therapy and clarification d, activating resources e,
generating, positive expectancies, normalization)
The principle of mindfulness based on “Mindfulness-Based
Cognitive Therapy” f
Maintenance
(Week 18–20)
Not intended as an actual therapy session. Overall
review, consolidation of what has been achieved, and
reiterating the individual strategies involved.
Discussion potentially difficult situations and
planning of coping methods.
Analogs to the standard treatment procedure week
18–20.
Notes. Additional components of the Standard PLUS condition are presented in italics. a Lukens and McFarlane,
2005; b Gauggel et al., 2003; c Fuster, 1997; d Greenberg, 2002; e Flückiger et al. 2009.; f Segal, Williams and
Teasdale, 2002.
4. Power Analysis
According to power considerations based on previous studies [67,71], we planned to include 72
patients to show a difference of three points on the BDI-II reaching the level of significance (p < 0.05).
Due to the much slower than anticipated recruitment rate over time, the recruitment had to finish
before reaching this target.
5. Statistical Analysis
Group differences in demographics and between-group effects at pre-assessment were
analyzed by using chi-square tests and two-tailed t-tests. All statistical analyses for the primary
outcome and all secondary outcomes were conducted by using intent-to-treat analysis, using the
last-value-carried-forward (LOCF) method to account for missing data. Between-group differences at
post-treatment and follow-up were analyzed using univariate analyses of covariance (ANCOVAs) using
pre-treatment scores as covariate [72]. Within-group changes in each group from pre- to post-treatment
and from pre- to follow-up assessment were tested by paired t-tests. Hedge’s g was calculated as effect
size (ES) for within-group changes. Between-group effect sizes were calculated as the difference of
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within-effect sizes between the two groups. In addition, the long-term treatment effect for the primary
outcome was analyzed using a repeated-measures ANOVA with a time (baseline, post-treatment, and
follow-up scores) and a group factor. Pairwise differences were measured using paired t-tests with a
Bonferroni correction. Because of the relatively small sample size, we also conducted non-parametric
tests to complement the parametric tests described above. All analyses were performed in IBM SPSS
Statistics version 25.
6. Results
6.1. Preliminary analyses
Table 2 shows the demographic and injury characteristics of the study sample. There were no
significant differences between the two groups regarding age, gender, marital status, employment,
neurological disorders, and time since injury at baseline.
Table 2. Sample characteristics for the Standard PLUS and Standard treatment.
PLUS
(n = 13)
Standard
(n = 12) Statistic
Age, years (SD) 50.8 (7.8) 45.6 (12.6) t(23) = −1.24, p = 0.22
Gender, n (%) χ2(1) = 0.05, p = 0.82
Male 6 (46.1) 5 (41.6)
Female 7 (53.9) 7 (58.4)
Marital status, n (%) χ2(2) = 1.22, p = 0.54
Single/living alone 2 (15.4) 4 (33.3)
Married/living together 9 (69.2) 6 (50.0)
Divorced 2 (15.4) 2 (16.7)
Education in years (SD) 12.4 (1.1) 12.6 (2.9) t(23) = 0.17, p = 0.86
Employment, n (%) χ2(2) = 1.10, p = 0.56
Self-Employed / Partner 5 (38.4) 6 (50.0)
Student 1 (7.8) 0
Sick pay/unfit for work 7 (53.8) 6 (50.0)
Neurological disorder, n (%) χ2(4) = 3.10, p = 0.54
Ischemic stroke 6 (46.1) 9 (75.0)
Hemorrhagic stroke 3 (23.1) 2 (16.7)
Traumatic brain Injury 2 (15.4) 1 (8.3)
Tumor 1 (7.7) 0 (0.0)
Encephalitis 1 (7.7) 0 (0.0)
Time since injury, months (SD) 14.1 (13.4) 19.6 (25.7) t(23) = 0.67, p = 0.50
Table 3 shows the descriptives of the questionnaire assessments of both groups at each time point
(baseline, post-treatment, and 6-month follow-up). At baseline, there were no differences between the
two groups on most of the measures. However, there was a significant difference between the two
groups regarding illness awareness from the relatives’ perspective, (t(20) = 2.30, p = 0.03; U = 28.0,
p = 0.03).
In total, 3 of 25 participants (12%, all ischemic stroke patients) did not complete the post-assessment
questionnaires. Dropout analyses revealed no significant differences on all baseline assessments
regarding two-tailed t-tests (ps = 0.078– 0.98) as well as non-parametric U-test (ps = 0.12–0.97).
All patients, who provided post-treatment data, also completed the follow-up assessment.
The average number of therapy sessions in the Standard PLUS group was 20.6 (SD = 5.0), and 18.3
(SD = 4.1) in the standard group. There was no significant difference between the groups regarding
number of sessions that patients received (t(23) = −1.27, p = 0.21; U = 57.0, p = 0.25).
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Table 3. Descriptives of outcome measures over time.
Baseline Post Follow-up
Measure M SD
Between-Group 1
M SD M SD
df T a U b
BDI-II 23 −1.07 58.00
PLUS 21.77 9.56 11.15 5.13 10.92 4.11
Standard 17.92 8.24 10.50 5.50 8.00 4.59
MFS 22 −0.81 57.00
PLUS 9.92 2.67 7.50 2.68 7.00 2.82
Standard 8.83 3.74 6.58 2.74 6.91 3.31
WHOQol 23 −1.02 54.00
PLUS 91.00 12.75 95.53 13.08 96.77 11.00
Standard 86.00 11.42 94.41 9.34 95.16 10.33
ADS 23 −0.31 72.00
PLUS 78.15 8.07 73.38 10.94 72.83 8.70
Standard 76.92 11.34 72.50 9.42 72.84 10.63
TSK_RU 23 1.08 61.00
PLUS 25.69 7.79 25.23 7.99 23.15 7.38
Standard 28.83 7.38 23.83 5.65 23.91 6.51
TSK_SS 23 −0.41 71.50
PLUS 36.00 7.38 38.07 4.87 38.69 4.99
Standard 34.83 6.49 38.33 6.28 38.08 5.93
TSK_BA 23 −1.21 59.50
PLUS 37.08 5.48 36.38 4.85 36.23 6.71
Standard 33.75 8.09 35.50 6.72 34.25 7.24
TSK_SI 23 0.57 71.00
PLUS 25.77 6.07 25.61 6.55 24.38 7.38
Standard 27.33 7.63 28.58 6.93 26.33 8.56
TSK_SR 23 −0.28 71.50
PLUS 8.54 4.01 8.15 3.60 7.92 4.55
Standard 8.08 4.23 8.83 3.29 7.33 2.87
AQ_R 20 2.30 * 28.00*
PLUS 33.92 5.01 40.08 5.90 38.25 6.09
Standard 39.20 5.75 42.30 6.03 42.20 5.78
AQ_C 23 −1.39 54.50
PLUS 46.00 3.13 50.23 3.32 —— ——
Standard 43.75 4.86 48.16 6.13 —— ——
AQ_P 23 −0.08 72.50
PLUS 37.77 5.70 40.92 6.73 39.61 6.64
Standard 37.58 6.24 40.75 5.92 40.91 6.18
RAS 20 −1.19 44.50
PLUS 25.17 2.16 24.91 1.83 26.79 4.26
Standard 23.90 2.80 25.50 3.34 24.90 2.88
ERSQ 23 −1.18 58.00
PLUS 70.92 14.54 85.00 13.69 78.46 13.72
Standard 52.50 20.80 66.91 15.29 71.00 17.29
Notes. BDI-II = Beck Depression Inventory—Second Edition; MFS = Mental Fatigue Scale; AQ_R = Awareness
Questionnaire Relative; AQ_C = Awareness Questionnaire Clinician; AQ_P = Awareness Questionnaire Patient;
RAS = Relationship Assessment Scale; ERSQ = Emotion Regulations Skills Questionnaire; WHOQOL = World
Health Organization Quality of Life; ADS = Acceptance Disability Scale; TSK = Trier Coping with Disease Scales;
TSK_RU = Rumination; TSK_SS = Seeking social support, TSK_BA = Avoidance, TSK_SI = Information seeking,
TSK_SR = Seeking help in religion. 1 Between-groups differences at baseline using t-test a and U-test b, * p < 0.05.
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6.2. Intervention Effects at Post-Treatment
Analyses of treatment outcome at post-treatment as well as respective within- and between-group
effect sizes are reported in Table 4. Regarding the primary outcome, paired t-tests showed a significant
within-group decrease in depressive symptoms measured by the BDI-II in both groups. Effect sizes were
in the large range. A univariate ANCOVA controlling for pre-treatment depressive symptoms showed
no significant difference between the two groups for depressive symptom scores post-treatment.
Table 4. Results of analyses of covariance at post-treatment (T2) controlled for baseline (T1) and within-
and between-group effect sizes at post-treatment.
Measure Group
Mean
Difference
(T1-T2)
95% CI
Within-Group Between-Group
df T Effect Size df F Effect Size 1
BDI-II
PLUS 10.70 (2.01–19.38) 12 3.53 ** 1.32 1,22 <0.01 0.30Standard 7.33 (1.51–13.14) 11 3.51 ** 1.02
MFS
PLUS 2.90 (0.51–5.29) 11 2.59 * 0.87 1,21 0.15 0.22Standard 2.33 (0.84–3.82) 11 4.18 ** 0.65
WHOQol PLUS −6.20 (−13.76–1.36) 12 −1.61 −0.34 1,22 0.35 −0.43Standard −7.78 (−13.87–−1.67) 11 −3.38 ** −0.77
ADS
PLUS 6.10 (−1.97–14.17) 12 1.64 0.48 1,22 <0.01 0.07Standard 3.11 (−1.95–8.17) 11 2.41 * 0.41
TSK_RU
PLUS 2.01 (−2.68–6.68) 12 0.22 0.06 1,22 2.19 −0.68Standard 4.89 (1.90–7.87) 11 4.10 ** 0.74
TSK_SS
PLUS −3.00 (−7.66–1.66) 12 −1.23 −0.32 1,22 0.24 −0.21Standard −2.89 (−6.44–0.66) 11 −2.63 * −0.53
TSK_BA
PLUS 1.20 (−2.56–4.96) 12 0.53 0.13 1,22 0.22 0.10Standard −2.89 (−8.11–2.33) 11 −0.96 −0.23
TSK_SI
PLUS −0.10 (−6.00–5.80) 12 0.07 0.02 1,22 0.84 −0.14Standard −2.22 (−7.91–3.47) 11 −0.65 −0.16
TSK_SR
PLUS 0.40 (−0.99–1.79) 12 0.77 0.08 1,22 1.18 −0.10
Standard −1.33 (−3.67–1.01) 11 −0.79 −0.18
AQ_R PLUS −6.40 (−9.65–−3.14) 11 −4.86 *** −1.09 1,19 0.56 0.59Standard −3.67 (−7.43–0.09) 9 −1.97 −0.50
AQ_C PLUS −4.80 (−7.27–−2.32) 12 −4.25 *** −1.30 1,22 0.03 0.51Standard −4.11 (−7.07–−1.14) 11 −3.92 ** −0.79
AQ_P PLUS −2.50 (−5.22–0.22) 12 −2.91 * −0.50 1,22 <0.01 0.01Standard −3.22 (−6.74–0.29) 11 −2.74 * −0.49
RAS
PLUS 0.00 (−1.01–1.01) 11 0.61 0.14 1,19 2.23 −0.36Standard −1.78 (−4.14–0.58 9 −1.71 −0.50
ERSQ PLUS −14.50 (−28.40–−0.59) 12 −2.84 * −0.97 1,22 7.56 * 0.21Standard −9.89 (−20.82–1.04) 11 −0.93 −0.76
Notes. BDI-II = Beck Depression Inventory—Second Edition; MFS = Mental Fatigue Scale; AQ_R = Awareness
Questionnaire Relative; AQ_C = Awareness Questionnaire Clinician; AQ_P = Awareness Questionnaire Patient;
RAS = Relationship Assessment Scale; ERSQ = Emotion Regulations Skills Questionnaire; WHOQOL = World
Health Organization Quality of Life; ADS = Acceptance Disability Scale; TSK = Trier Coping with Disease Scales;
TSK_RU = Rumination; TSK_SS = Seeking social support, TSK_BA = Avoidance, TSK_SI = Information seeking,
TSK_SR = Seeking help in religion. 1 Delta of within-group effect sizes at post-assessment. * p < 0.05; ** p < 0.01;
*** p < 0.001.
Regarding secondary outcomes, paired t-tests revealed significant within-group changes in the
Standard PLUS group regarding mental fatigue, awareness from all three perspectives, and emotion
regulation skills. Significant within-group changes for the standard group were found for mental
fatigue, quality of life, acceptance of the disability, rumination, and seeking social support, as well as
awareness for the clinician and the patient. Univariate ANCOVAs controlling for pre-treatment scores
showed significant differences between the Standard PLUS and Standard group regarding emotion
regulation skills measures with the ERSQ at post-treatment, whereas there was no difference between
the two groups regarding all the other secondary outcomes at post-treatment. Independent t-tests
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(t(23) = −3.10, p = 0.005) and non-parametric Mann–Whitney U-Test (p = 0.004) showed the same
results for the ERSQ.
Regarding the average score of all three individualized treatment goals, i.e., GAS, the Standard
PLUS (M = 2.47 SD = 1.28) and the Standard group (M = 2.57 SD = 1.29), did not differ significantly
from each other (t(20) = 0.17, p = 0.86; U = 58.0, p = 0.89).
Based on the criteria for reliable change (reduction of pre-treatment BDI-II scores of at least 10
points [73]), 8 patients out of 13 (62%) of the Standard PLUS condition and 4 patients out of 12 (33%) of
the Standard group were classified as having achieved a reliable change from pre- to post-treatment.
However, statistically, the groups did not differ significantly regarding the number of patients reaching
a reliable change χ2 (1, n =25) = 1.98, p = 0.16.
6.3. Intervention Effects at Follow-Up Assessment
Results regarding the follow-up assessment are described in Table 5. Regarding the primary
outcome, paired t-tests demonstrated significant within-group changes on depressive scores for the
Standard PLUS as well as for the standard group.
Table 5. Results of analyses of covariance at follow-up (T3) controlled for baseline (T1) and within- and
between-group effect sizes at follow-up.
Measure Group
Mean
Difference
(T1-T2)
95% CI
Within-Group Between-Group
df T Effect Size df F Effect Size 1
BDI-II
PLUS 10.30 (1.76–18.83) 12 3.65 ** 1.42 1,22 1.91 −0.02Standard 10.11 (5.06–15.15) 11 5.46 *** 1.44
MFS
PLUS 3.30 (1.06–5.53) 11 3.41 ** 1.02 1,21 0.32 0.50Standard 1.78 (−0.24–3.80) 11 2.73 * 0.52
WHOQol PLUS −8.20 (−16.46–0.06) 12 −1.83 −0.46 1,22 0.35 −0.34Standard −9.55 (−17.65–−1.45) 11 −3.17 ** −0.80
ADS
PLUS 6.70 (−1.22–14.62) 12 1.90 0.62 1,22 0.05 0.26Standard 3.67 (−0.94–8.28) 11 2.12 0.36
TSK_RU
PLUS 2.54 (2.95–6.87) 12 0.22 0.32 1,22 2.19 −0.36Standard 4.91 (−2.00–7.07) 11 4.11 ** 0.68
TSK_SS
PLUS −2.72 (−6.39–1.01) 12 −1.23 −0.42 1,22 0.24 −0.09Standard −3.33 (−6.75–0.25) 11 −2.63 * −0.51
TSK_BA
PLUS −0.81 (−2.73–4.42) 12 0.53 0.14 1,22 0.22 0.06Standard −0.50 (−5.48–4.48) 11 −0.96 −0.08
TSK_SI
PLUS 1.43 (−4.01–6.78) 12 0.07 0.19 1,22 0.84 0.07Standard 1.01 (−4.51–6.51) 11 −0.65 0.12
TSK_SR
PLUS 0.67 (−0.74–1.97) 12 0.77 0.13 1,22 1.18 −0.08Standard 0.81 (−0.96–2.46) 11 −0.79 0.21
AQ_R PLUS −5.10 (−7.65–−2.54) 11 −3.76 ** −0.76 1,19 0.08 0.26Standard −3.22 (−6.29–−0.15) 9 −1.15 −0.50
AQ_P PLUS −1.60 (−4.97–1.77) 12 −1.52 −0.30 1,22 0.73 −0.21Standard −2.67 (−6.29–0.95) 11 −2.74 * −0.51
RAS
PLUS −0.40 (−2.15–1.35) 11 −0.64 −0.42 1,19 0.03 0.08Standard −1.11 (−3.33–1.11) 9 −1.15 −0.34
ERSQ PLUS −7.30 (−23.23–8.63) 12 −1.39 −0.51 1,22 0.52 −0.42Standard −13.89 (−24.86–−2.91) 11 −1.87 −0.93
Notes. BDI-II = Beck Depression Inventory—Second Edition; PHQ-9, Patient Health Questionnaire; Self-Assessment
Questionnaire MFS = Mental Fatigue Scale; AQ_R = Awareness Questionnaire Relative; AQ_C = Awareness
Questionnaire Clinician; AQ_P = Awareness Questionnaire Patient; RAS = Relationship Assessment Scale; ERSQ
= Emotion Regulations Skills Questionnaire; WHOQOL = World Health Organization Quality of Life; ADS =
Acceptance Disability Scale; TSK = Trier Coping with disease Scales; TSK_RU = Rumination; TSK_SS = Seeking
social support, TSK_BA = Avoidance, TSK_SI = Information seeking, TSK_SR = Seeking help in religion. 1 Delta
within group at follow-up-assessment. * p < 0.05; ** p < 0.01; *** p < 0.001.
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Univariate ANCOVAs controlling for pre-treatment scores showed no significant differences
between the two groups on any outcome measure at follow-up assessment. Independent t-tests
(ps = 0.11–0.99) and non-parametric Mann–Whitney tests (ps = 0.07–0.99) for follow-up scores showed
the same pattern.
Within- and between-group effect sizes at follow-up are presented in Table 5. From baseline to
follow-up assessment, large (ES > 0.80) within-group effect sizes were found for the Standard PLUS
group on BDI-II and mental fatigue and moderate (ES = 0.50–0.79) within-group effects were found on
acceptance of disability and awareness of relatives. Large within-group effect sizes (ES > 0.80) for pre-
to follow-up-treatment were found for the standard group on depressive symptoms, quality of life,
and emotion regulation, moderate within-group effects (ES = 0.59–0.79) were found on mental fatigue,
rumination, seeking social support, and awareness from the patient and the relative perspective.
Finally, a repeated-measures ANOVA of time (pre-treatment, post-treatment, follow-up) x group
(Standard PLUS, Standard) for the primary outcome was conducted. Mauchly’s tests indicated that
the assumption of sphericity had been violated for the main effect time, χ2(2) = 19.83, p < 0.001.
Therefore, degrees of freedom were corrected using Greenhouse–Geisser estimates of sphericity
(ε = 0.63 for the main effect time). Repeated-measures ANOVA resulted in a significant main effect
of time, F(1.25, 28.85) = 26.52, p < 0.001, while the interaction time x group was not significant,
F(1.25, 28.88) = 0.56, p = 0.49. The effect sizes for the main effect of time was ηp2 = 0.722 and for the
interaction, time x group was ηp2 = 0.044.
7. Discussion
An acquired brain injury is a drastic incident that has major influences on affected people
and their social network. Thus, such events are often accompanied by far-reaching adjustments
to be made that go along with mood impairments. The present study compares two individual
psychological treatments for patients diagnosed with an AjD after an ABI in a randomized-controlled
trial (RCT), i.e., an integrated cognitive–behavioral treatment combined with a neuropsychological
therapy (Standard PLUS) vs. a neuropsychological treatment alone (Standard). We hypothesized
that the integrated treatment is more effective regarding reduction of depressive symptoms than the
standard neuropsychological treatment alone. The results did not support this hypothesis. Whereas
both treatments showed large effects on depressive symptoms at post-treatment and at 6-month
follow-up, there was no significant difference between the two treatments. The large within-group
effect size from baseline to post-treatment for the Standard PLUS condition was in the same range as
the effect of the same treatment in an uncontrolled pilot study [46].
The present results regarding depressive symptoms are in line with studies that have compared
two active treatments in an RCT in major depression [74]. However, the within-group effect sizes
were large and comparable with a meta-analysis that reported beneficial results of psychological
intervention for patients after an ABI [42]. Nevertheless, the effect sizes were below benchmarks
of within-group effect sizes for depressive symptoms in psychotherapy studies for depression [75].
These results demonstrate that the treatment of patients with acquired brain injuries is especially
challenging since several impairments (e.g., neuropsychological and emotional deficits) have to be
incorporated at the same time in one treatment [76,77]. Moreover, residual depressive symptoms may
partly be attributable to acquired neurological and neuropsychological deficits and could hamper
the rehabilitation process and outcome [78,79]. In comparison to other studies with ABI patients
comparing active treatments, the standard treatment in the present study may have been a too strong
comparator that was too similar to the integrative treatment. Modern neuropsychological interventions
are not only limited to restitution and compensation of neuropsychological deficits but also incorporate
coping with consequences of the injury as well as the implementation of selected cognitive–behavioral
interventions [80,81]. The mentioned result is in line with results of other studies in this population
which did not find differences between active conditions when compared to a passive control group [82].
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Whereas there was a significant between-group difference for emotion regulation skills at
post-treatment, this difference disappeared until the 6-month follow-up. For the other secondary
outcomes, there were no group differences at post-treatment or follow-up. Importantly, in both groups,
no change was observed regarding the relationship quality. One reason could be that both treatments
focused mainly on intrapersonal factors and not on interpersonal aspects, and future treatments should
also incorporate a stronger focus on interpersonal factors. Since a brain injury has not only a major
impact on the patient alone but also on her or his social environment, future studies might need to
regularly incorporate significant others into the psychological treatment.
For many patients, depressive symptoms are a major problem after ABI, may persist for a long time
after the injury, and often limit rehabilitation outcomes [83]. Post-stroke aftermath, such as enduring
cognitive impairment after stroke [84], a persistent loss of energy, or a permanent sick leave from job [21],
is illustrative of the complexity of treatment in mood disorders after ABI. Therefore, the prevention of
mood disorders should be an important part of the treatment after ABI. A Cochrane review revealed
promising results and found a small significant effect for psychotherapy in the prevention of post-stroke
depression [85]. Moreover, in a study from Robinson and colleagues [86] comparing selective serotonin
reuptake inhibitors (SSRI), problem-solving therapy, and placebo, both SSRIs and problem-solving
therapy were found to be superior to placebo in the prevention of mood disorders after ABI. Therefore,
it might be important for stroke survivors to receive specific neuropsychological therapy in combination
with psychotherapeutic interventions to prevent chronic disorder courses. Notwithstanding, more
systematic research is needed to evaluate the long-term effectiveness of prevention therapy for mood
disorders after ABI.
The present study has some noteworthy limitations. A first important shortcoming is the small
sample size of the present study. Future studies might consider broadening the inclusion criteria
in order to reach a sample size large enough to compare two active treatments. A second point is
that standard neuropsychological therapy followed a holistic approach [87] that incorporated many
CBT components (e.g., behavior activation, coping strategies, operant conditioning strategies, and a
rest management program) [65]. A recent published meta-analysis showed that neuropsychological
therapy (e.g., computerized cognitive-training) was associated with improvement in depressive
symptoms and everyday functioning [88]. Thus, it can be assumed that the neuropsychological
treatment alone has had a positive impact on mood. In that sense, it is not possible to differentiate
the effects of the combination therapy from the neuropsychological therapy. Lastly, there were no
measures of adherence for both treatments. Since therapists, licensed as neuropsychologist and
CBT psychotherapist, provided treatments in both conditions, spillover effects may have occurred
that ultimately led to similar outcomes in both conditions. Furthermore, the sample in the present
study was rather heterogeneous with regard to the ABI. Future studies might consider investigating
more homogenous samples. Potential benefits may include the fact that subgroups with regard to
corresponding neurological deficits may profit more from specific psychotherapeutic interventions (e.g.,
emotion-focus interventions). However, more homogenous samples would limit generalizability and
further reduce the feasibility of a study. In addition, future studies might consider a shorter post-injuries
time point and include patients, which have already reached a certain level of neurological functioning.
In sum, we did not find that an integrated treatment approach for the treatment of patients with
an adjustment disorder after an ABI is superior to a standard approach. Nevertheless, both treatments
showed medium to large within-group effects sizes on most measures for patients suffering from an
AjD after ABI. To the best of our knowledge, this is the first trial investigating the effectiveness of
an integrative treatment compared with an active control condition on patients suffering from AjD
after ABI.
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